A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

NCT04814368 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Knee Osteoarthritis

Interventions

BIOLOGICAL: canakinumab
BIOLOGICAL: LNA043
OTHER: Placebo to canakinumab

Sponsor

Novartis Pharmaceuticals